Loading clinical trials...

The Moran AMD Genetic Testing Assessment Study | Clinical Trials | Clareo Health

COMPLETEDPHASE2

The Moran AMD Genetic Testing Assessment Study

A Phase 2 Study of the Value of Pre-symptomatic Genetic Risk Assessment for Age-Related Macular Degeneration

NCT05265624•Paul S. Bernstein

Summary

The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.

Eligibility

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Participants must be between 18 and 64 years of age.
•They must also be Caucasian as this genetic test is only validated in Caucasians.
•They can have a positive family history of AMD but this is not necessary.

Exclusion Criteria

•Personal history of AMD
•Non Caucasian
•Employee of the Moran or other eye care practice (likely to have more knowledge about AMD than a layperson)
•Personal history of prior genetic testing for AMD risk
•Anticipated cataract surgery in the upcoming year (can affect Macular Pigment measurement)
•Major psychiatric disorder

Locations (1)

University of Utah John A. Moran Eye Center

Salt Lake City, Utah, United States

Key Dates

Start Date

August 3, 2022

Primary Completion Date

July 12, 2024

Completion Date

July 12, 2024

Last Updated

October 1, 2025

Enrollment

ACTUAL participants

Conditions

Age-Related Macular DegenerationGenetic TestingNutritional Biomarkers

Interventions

Early disclosure of genetic testing results

BEHAVIORAL

Late disclosure of genetic testing results

BEHAVIORAL

Direct Discrimination of Quantum States by the Human Eye

NCT05913063

Age-Related Macular Degeneration

View study

RECRUITINGPHASE2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269

Geographic Atrophy Secondary to Age-related Macular Degeneration

View study

RECRUITINGPHASE4

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Moran AMD Genetic Testing Assessment Study

Inclusion Criteria

Exclusion Criteria

Direct Discrimination of Quantum States by the Human Eye

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Video Education With Result Dependent dIsclosure

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)